Qure.ai to scale up govt partnerships for health screenings in India

The company, which offers artificial intelligence tools for tuberculosis, lung cancer and stroke screening, currently generates less than 5% of its total revenue from India. But CEO and founder Prashant Warier sees a “significant opportunity” to tap into the public health market, especially given the country’s disproportionate tuberculosis burden.

According to the World Health Organization’s Global Tuberculosis Report 2025, India accounted for 25% of global TB cases in 2024. This challenge focuses largely on public health systems.

“When you look at tuberculosis, you see that tuberculosis occurs and one-quarter of tuberculosis cases in the world are in public sector government hospitals. So we said, ‘Why shouldn’t we solve the tuberculosis problem in India?'” Warier said in an interview. we said.

Kure.ai has sharpened its focus on government partnerships over the past year; Warier expects a strategic shift to yield significant results.

“As a market in India, we’re focused on providing TB solutions to the government of India, both state and central government. And we think there’s a significant opportunity there to build a large commercial organization for TB in India focused on the government of India,” Warier said. “We’ll see a lot of results around that in the next year or two.”

The company is currently collaborating with the Indian Council of Medical Research (ICMR) and the central government on tuberculosis screening programmes. Kure.ai has already secured significant partnerships at the state level in Goa, Karnataka and Jammu and Kashmir. Earlier this year, it began making its AI stroke screening tool available to the Punjab government for use in select district hospitals.

Warier noted that cracking the government market could significantly expand its reach in India. While Kure.ai works with 4,500 hospitals globally, only 5-10% are currently located in India. The company aims to add up to 3,000 hospitals worldwide this year.

“All of a sudden you’re rolling it out to 500 hospitals in one deployment… it’s growing now, maybe a disproportionate number of new additions will come from India,” he said.

Using the Public-Private Partnership model

Diagnostic players are increasingly using the Public-Private Partnership (PPP) model, which can provide a valuable basis for AI firms to integrate their technologies. Warier confirmed that Qure.ai plans to either engage with governments directly or partner with companies involved in PPPs.

Course.ai isn’t the only one following this path; Other healthcare AI firms like Niramai Health Analytix have also collaborated with state governments.

While India has potential for growth in the future, Course.ai’s current revenue engine comes from abroad. The United States accounts for approximately one-third of total revenue, followed by Europe with 10-15%, and the remainder comes from low- and middle-income countries.

Warier attributes the low commercial opportunity in India’s private sector to its smaller size compared to insured markets such as the US and its limited capacity to pay for advanced AI solutions.

The company plans to actively increase its penetration in European markets, including Germany, France, Spain and the Netherlands, and is considering acquisitions to gain market access or increase its product portfolio.

From a financial perspective, Que.ai saw its operating income increase by 24.5%. ₹175.5 crore in fiscal 2025, according to Entrackr. But rising costs increased their losses by 87.5%. ₹90 crore. Kure.ai raised a total of $121 million from investors including Peak XV Partners, HealthQuad, and Novo Holdings and was valued at $264 million in its last funding round in November 2024. Warier expects the company to become profitable in the next few years as global and Indian public sector initiatives gain momentum.